Translution Capital advises CombiGene (publ.)
Posted on 13. October 2021
Translution Capital advices CombiGene AB (publ.) on a deal securing a total funding package of up to SEK 509 million from Spark Therapeutics, a company within the Roche Group. We congratulate the CombiGene AB team on this successful deal.